[Infliximab].
Infliximab is a chimeric monoclonal antibody, which specifically binds to tumor necrosis factor (TNF-alpha) and blocks its activity. Based on previous evidence that TNF-alpha has been involved in the pathogenesis of psoriasis, multiple controlled trials have shown that infliximab has provided a high degree of clinical benefit in the treatment of psoriasis and psoriatic arthritis allowing a major and rapid improvement in these patients. We review several clinical trials, which have firmly established both efficacy and safety of Infliximab in the treatment of moderate to severe psoriasis and psoriatic arthritis.
Herrera
E
E
Servicio de Dermatología, Hospital Clínico Universitario Virgen de Victoria, Málaga, España. eherrera@uma.es
Habicheyn
S
S
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D018849:Controlled Clinical Trials as Topic; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008297:Male; D011247:Pregnancy; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab